Trial Profile
Urodynamic evaluation by pressure flow urodynamic study of the new α1A-adrenoceptor antagonist silodosin 8 mg qd in patients with benign prostatic obstruction. Explorative, single-arm, phase IV clinical study. Urodynamic evaluation by pressure flow urodynamic study of the new α1A-adrenoceptor antagonist silodosin 8 mg qd in patients with benign prostatic obstruction. Explorative, single-arm, phase IV clinical study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Silodosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Sponsors Recordati
- 10 Mar 2022 Status changed from recruiting to completed.
- 26 Dec 2017 New trial record